{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:12:34Z","timestamp":1788516754871,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"DOI":"10.1007\/s11883-026-01456-6","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:19:42Z","timestamp":1788513582000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral Incretin-Based Therapies for Weight Management"],"prefix":"10.1007","volume":"28","author":[{"given":"Henry Evan","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bonafede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpana P.","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"1456_CR1","doi-asserted-by":"crossref","unstructured":"Emmerich SD, Fryar CD. Obesity and severe obesity prevalence in adults: United States, August 2021\u2013August 2023 [Internet]. Centers for disease control and prevention; 2024 [cited 2025 Dec 23]. Available from: https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db508.htm","DOI":"10.15620\/cdc\/159281"},{"key":"1456_CR2","doi-asserted-by":"publisher","unstructured":"Okunogbe A, Nugent R, Spencer G, Powis J, Ralston J, Wilding J. Economic impacts of overweight and obesity: Current and future estimates for 161 countries. BMJ Global Health. 2022 Sept;7(9). https:\/\/doi.org\/10.1136\/bmjgh-2022-009773.","DOI":"10.1136\/bmjgh-2022-009773"},{"issue":"4","key":"1456_CR3","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s13679-023-00527-y","volume":"12","author":"C Koliaki","year":"2023","unstructured":"Koliaki C, Dalamaga M, Liatis S. Update on the obesity epidemic: After the sudden rise, is the upward trajectory beginning to flatten? Curr Obes Rep. 2023;12(4):514\u201327. https:\/\/doi.org\/10.1007\/s13679-023-00527-y.","journal-title":"Curr Obes Rep"},{"issue":"1","key":"1456_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/oby.23308","volume":"30","author":"KD Hall","year":"2021","unstructured":"Hall KD. Energy compensation and metabolic adaptation: The biggest loser study reinterpreted. Obesity. 2021;30(1):11\u20133. https:\/\/doi.org\/10.1002\/oby.23308.","journal-title":"Obesity"},{"key":"1456_CR5","doi-asserted-by":"publisher","first-page":"116471","DOI":"10.1016\/j.bcp.2024.116471","volume":"2","author":"Z Ke","year":"2024","unstructured":"Ke Z, Ma Q, Ye X, Wang Y, Jin Y, Zhao X, et al. Peptide GLP-1 receptor agonists: From injection to oral delivery strategies. Biochem Pharmacol. 2024;2:116471. https:\/\/doi.org\/10.1016\/j.bcp.2024.116471.","journal-title":"Biochem Pharmacol"},{"key":"1456_CR6","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2147\/ppa.s463354","volume":"18","author":"J Myers","year":"2024","unstructured":"Myers J, Van Dam J, Imran M, Hashim M, Dhalla A. Preference for a novel oral alternative to parenterally administered medications. Patient Prefer Adherence. 2024;18:1547\u201362. https:\/\/doi.org\/10.2147\/ppa.s463354.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"1456_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2337\/ds20-0033","volume":"34","author":"EB Hearn","year":"2021","unstructured":"Hearn EB, Sherman JJ. Injection-site nodules associated with once-weekly subcutaneous administration of semaglutide. Diabetes Spectr. 2021;34(1):73\u20135. https:\/\/doi.org\/10.2337\/ds20-0033.","journal-title":"Diabetes Spectr"},{"issue":"5","key":"1456_CR8","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s11154-022-09735-8","volume":"23","author":"VR Aroda","year":"2022","unstructured":"Aroda VR, Blonde L, Pratley RE. A new era for oral peptides: Snac and the development of oral semaglutide for the treatment of type 2 diabetes. Reviews Endocr Metabolic Disorders. 2022;23(5):979\u201394. https:\/\/doi.org\/10.1007\/s11154-022-09735-8.","journal-title":"Reviews Endocr Metabolic Disorders"},{"issue":"10","key":"1456_CR9","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s40262-021-01025-x","volume":"60","author":"RV Overgaard","year":"2021","unstructured":"Overgaard RV, Navarria A, Ingwersen SH, B\u00e6kdal TA, Kildemoes RJ. Clinical pharmacokinetics of oral semaglutide: Analyses of data from Clinical Pharmacology Trials. Clin Pharmacokinet. 2021;60(10):1335\u201348. https:\/\/doi.org\/10.1007\/s40262-021-01025-x.","journal-title":"Clin Pharmacokinet"},{"issue":"10403","key":"1456_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/s0140-6736(23)01185-6","volume":"402","author":"FK Knop","year":"2023","unstructured":"Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, et al. Oral semaglutide 50\u00a0mg taken once per day in adults with overweight or obesity (OASIS 1): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705\u201319. https:\/\/doi.org\/10.1016\/s0140-6736(23)01185-6.","journal-title":"Lancet"},{"key":"1456_CR11","unstructured":"Kadowaki T, Heftdal LD, Ko H-J, Overvad M, Shimomura I. Oral semaglutide in an East Asian population with overweight or obesity, with or without type 2 diabetes: The Oasis 2 randomized clinical trial [Internet]. U.S. National Library of Medicine; 2025 [cited 2026 Feb 16]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/40758358\/"},{"key":"1456_CR12","doi-asserted-by":"publisher","unstructured":"Wharton S, Lingvay I, Bogdanski P, Duque do Vale R, Jacob S, Karlsson T, et al. Oral semaglutide at a dose of 25\u00a0mg in adults with overweight or obesity. New Engl J Med 2025 Sept 18;393(11):1077\u201387. https:\/\/doi.org\/10.1056\/nejmoa2500969","DOI":"10.1056\/nejmoa2500969"},{"issue":"11","key":"1456_CR13","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/s2213-8587(25)00226-8","volume":"13","author":"S Wharton","year":"2025","unstructured":"Wharton S, Freitas P, Hjelmes\u00e6th J, Kabisch M, Kandler K, Lingvay I, et al. Once-weekly semaglutide 7\u00b72\u00a0mg in adults with obesity (step up): A randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949\u201363. https:\/\/doi.org\/10.1016\/s2213-8587(25)00226-8.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1456_CR14","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.17141","author":"K Drygalski","year":"2025","unstructured":"Drygalski K, Pastuszak K, Modzelewska B. The assessment of non-inferiority of oral vs. subcutaneous semaglutide: A systematic review and meta-analysis. Pol Archives Intern Med. 2025. https:\/\/doi.org\/10.20452\/pamw.17141.","journal-title":"Pol Archives Intern Med"},{"issue":"24","key":"1456_CR15","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/nejmoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/nejmoa2307563.","journal-title":"N Engl J Med"},{"issue":"20","key":"1456_CR16","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/nejmoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392(20):2001\u201312. https:\/\/doi.org\/10.1056\/nejmoa2501006.","journal-title":"N Engl J Med"},{"key":"1456_CR17","doi-asserted-by":"publisher","unstructured":"Sloop KW, Cox AL, Wainscott DB, White A, Droz BA, Stutsman C, et al. The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Sci Transl Med. 2024;16(778). https:\/\/doi.org\/10.1126\/scitranslmed.adp5765.","DOI":"10.1126\/scitranslmed.adp5765"},{"issue":"4","key":"1456_CR18","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s13300-024-01554-1","volume":"15","author":"X Ma","year":"2024","unstructured":"Ma X, Liu R, Pratt EJ, Benson CT, Bhattachar SN, Sloop KW. Effect of food consumption on the pharmacokinetics, safety, and tolerability of once-daily orally administered Orforglipron (LY3502970), a non-peptide GLP-1 receptor agonist. Diabetes Therapy. 2024;15(4):819\u201332. https:\/\/doi.org\/10.1007\/s13300-024-01554-1.","journal-title":"Diabetes Therapy"},{"issue":"5","key":"1456_CR19","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1111\/dom.16275","volume":"27","author":"M Look","year":"2025","unstructured":"Look M, Dunn JP, Kushner RF, Cao D, Harris C, Gibble TH, et al. Body composition changes during weight reduction with Tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metabolism. 2025;27(5):2720\u20139. https:\/\/doi.org\/10.1111\/dom.16275.","journal-title":"Diabetes Obes Metabolism"},{"issue":"18","key":"1456_CR20","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1056\/nejmoa2511774","volume":"393","author":"S Wharton","year":"2025","unstructured":"Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796\u2013806. https:\/\/doi.org\/10.1056\/nejmoa2511774.","journal-title":"N Engl J Med"},{"key":"1456_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04386-7","author":"LJ Aronne","year":"2026","unstructured":"Aronne LJ, Horn DB, le Roux CW, Chao AM, Ho W, Halpern B, et al. Orforglipron for maintenance of body weight reduction: The double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026. https:\/\/doi.org\/10.1038\/s41591-026-04386-7.","journal-title":"Nat Med"},{"issue":"9","key":"1456_CR22","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.1111\/dom.16534","volume":"27","author":"C Buckeridge","year":"2025","unstructured":"Buckeridge C, Cobain S, Bays HE, Matsuoka O, Fukushima Y, Halstead P, et al. Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study. Diabetes Obes Metabolism. 2025;27(9):4915\u201326. https:\/\/doi.org\/10.1111\/dom.16534.","journal-title":"Diabetes Obes Metabolism"},{"issue":"1","key":"1456_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/dom.16005","volume":"27","author":"NB Amin","year":"2024","unstructured":"Amin NB, Frederich R, Tsamandouras N, Haggag AZ, Schuster T, Zmuda W, et al. Evaluation of an oral small-molecule glucagon\u2010like peptide\u20101 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose\u2010ranging, phase 2, randomized, placebo\u2010controlled study. Diabetes Obes Metabolism. 2024;27(1):215\u201327. https:\/\/doi.org\/10.1111\/dom.16005.","journal-title":"Diabetes Obes Metabolism"},{"issue":"4","key":"1456_CR24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/jcph.2371","volume":"64","author":"DJ Fediuk","year":"2023","unstructured":"Fediuk DJ, Gorman DN, Stoddard S, Zhang Y, Ogden AG, Winton JA, et al. Effect of renal impairment on the pharmacokinetics of a single oral dose of Danuglipron in participants with type 2 diabetes. J Clin Pharmacol. 2023;64(4):449\u201360. https:\/\/doi.org\/10.1002\/jcph.2371.","journal-title":"J Clin Pharmacol"},{"key":"1456_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04476-6","author":"J Rosenstock","year":"2026","unstructured":"Rosenstock J, Lingvay I, Ryan D, Jastreboff AM, Kushner R, Acosta A, et al. Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: A randomized, double-blind, placebo-controlled phase 2B trial. Nat Med. 2026. https:\/\/doi.org\/10.1038\/s41591-026-04476-6.","journal-title":"Nat Med"},{"issue":"10547","key":"1456_CR26","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/s0140-6736(26)00748-8","volume":"407","author":"MJ Davies","year":"2026","unstructured":"Davies MJ, Aroda VR, Rosenstock J, Capehorn M, Pedersen SD, Morizzo E, et al. Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (Vista): A multicentre, phase 2, randomised, placebo-controlled clinical trial. Lancet. 2026;407(10547):2503\u201314. https:\/\/doi.org\/10.1016\/s0140-6736(26)00748-8.","journal-title":"Lancet"},{"key":"1456_CR27","doi-asserted-by":"publisher","unstructured":"Gu W, Zhang L, Li L, Wei D, Qifu L, Zong Y, et al. 865-P: Efficacy and safety of a novel oral small molecule GLP-1RA in Chinese obese adults without diabetes. Diabetes. 2025;74(Supplement1). https:\/\/doi.org\/10.2337\/db25-865-p.","DOI":"10.2337\/db25-865-p"},{"key":"1456_CR28","doi-asserted-by":"publisher","unstructured":"Bi Y, Zhu D, Li X, Chen S, Ye Z, Zhou Q, et al. 2816-lb: Efficacy and safety of oral ribupatide (HRS9531) in adults with obesity: A phase 2 trial. Diabetes. 2026;75(Supplement1). https:\/\/doi.org\/10.2337\/db26-2816-lb.","DOI":"10.2337\/db26-2816-lb"},{"issue":"Suppl 1","key":"1456_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000551826","volume":"19","author":"PJ Hedges","year":"2026","unstructured":"Hedges PJ, Bays H, Freilich B, Bowman K, Neutel B, Steele B, Modesto K, Ji S, Lian B. Treatment with oral VK2735 results in significant weight loss: the randomized, placebo-controlled, dose-finding VENTURE-Oral study [abstract PO4.260]. In: 33rd European Congress on Obesity (ECO 2026) \u2013 Abstracts. Obes Facts. 2026;19(Suppl 1):1\u2013661. https:\/\/doi.org\/10.1159\/000551826.","journal-title":"Obes Facts"},{"issue":"8","key":"1456_CR30","doi-asserted-by":"publisher","first-page":"7247","DOI":"10.1111\/dom.70919","volume":"28","author":"W Michalak","year":"2026","unstructured":"Michalak W, B\u00f8g M, Bendixen T, Chowdhury R, Cowley P, Laugesen C, et al. Oral semaglutide 25\u00a0mg versus Orforglipron 36\u00a0mg in obesity: A population-adjusted indirect treatment comparison. Diabetes Obes Metabolism. 2026;28(8):7247\u201356. https:\/\/doi.org\/10.1111\/dom.70919.","journal-title":"Diabetes Obes Metabolism"},{"issue":"1","key":"1456_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/nejmoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26\u201336. https:\/\/doi.org\/10.1056\/nejmoa2416394.","journal-title":"N Engl J Med"},{"key":"1456_CR32","doi-asserted-by":"publisher","unstructured":"West S, Scragg J, Aveyard P, Oke JL, Willis L, Haffner SJ, et al. Weight regain after cessation of medication for weight management: Systematic review and meta-analysis. BMJ. 2026;392. https:\/\/doi.org\/10.1136\/bmj-2025-085304.","DOI":"10.1136\/bmj-2025-085304"},{"issue":"11","key":"1456_CR33","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/nejmoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002. https:\/\/doi.org\/10.1056\/nejmoa2032183.","journal-title":"N Engl J Med"},{"issue":"3","key":"1456_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/nejmoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316. https:\/\/doi.org\/10.1056\/nejmoa2206038.","journal-title":"N Engl J Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01456-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01456-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01456-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:19:44Z","timestamp":1788513584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-026-01456-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1456"],"URL":"https:\/\/doi.org\/10.1007\/s11883-026-01456-6","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"APS receives institutional research funding from Eli Lilly & Company, Novo Nordisk and Viking Therapeutics and serves as an advisor\/consultant to Eli Lilly and company, Novo Nordisk and Sun Pharmaceuticals. HEC and MB have no competing interests to declare.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal subjects were used in this study. All studies with human subjects are published and followed ethical, institutional standards.","order":2,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"86"}}